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The activity of the fluoroquinolone flumequine was investigated against the fish pathogen Aeromonas
salmonicida and was compared with that of oxolinic acid. Flumequine was more active than oxolinic acid in
terms of its MIC against oxolinic acid-resistant isolates of A. salmonicida and was as active as oxolinic acid
against susceptible isolates. In contrast to oxolinic acid, flumequine was bactericidal, with only 1% of the
bacteria surviving 6 h of exposure to the drug at concentrations slightly above the MIC. Mutation to resistance
to flumequine was found to occur at a lower frequency than that to oxolinic acid. Hence, in vitro, flumequine
appears to possess some advantages over oxolinic acid against this fish pathogen.
Aeromonas salmonicida is the causative agent of furuncu-
losis, an important disease in farmed salmonids in Scotland,
Norway, and Canada. The control of furunculosis is depen-
dent upon the use of antibiotics, commonly the 4-quinolone
oxolinic acid (1, 4). However, the early success achieved
with oxolinic acid is increasingly being compromised by the
development of resistance to the drug (5). In a previous
study (2), we reported the increased activity of newer
fluoroquinolones against A. salmonicida. However, it seems
unlikely that some of these compounds will become avail-
able for veterinary use in the United Kingdom in the near
future. In contrast, flumequine is a fluoroquinolone already
used in the aquaculture industry in Norway, although it is
not used in the United Kingdom. The in vitro activity of
flumequine against Scottish isolates of A. salmonicida was
therefore investigated to assess the potential of flumequine
as an alternative to oxolinic acid.
The MICs of oxolinic acid and flumequine were deter-
mined for 83 oxolinic acid-susceptible and -resistant isolates
of A. salmonicida, predominantly from natural outbreaks of
furunculosis at farm sites in Scotland. MICs were deter-
mined at 22°C by agar dilution on tryptone soy agar (TSA;
Oxoid) as described previously (2).
In terms of its MIC, flumequine was slightly more active
than oxolinic acid against both oxolinic acid-susceptible and
-resistant isolates of A. salmonicida, although the range of
flumequine MICs was much broader than those recorded for
oxolinic acid against resistant isolates (Table 1).
The bactericidal activities of the drugs were investigated
essentially as described by Lewin et al. (7) by using two
oxolinic acid-resistant isolates, MT364 and MT472, and two
oxolinic acid-susceptible isolates, MT363 and MT736 (Table
2). An overnight culture of the isolates containing approxi-
mately 108 CFU/ml was diluted 1 in 50 into fresh tryptic soy
broth (TSB; Oxoid) containing various concentrations of
antibacterial agents. The antibacterial concentrations fol-
lowed the arithmetic progression 1.5, 3, 5, and 9. Samples
were taken after 1, 3, and 6 h of incubation at 22°C and were
serially diluted in TSB. Percent survival was estimated by
viable count on TSA. Experiments were performed in trip-
licate, and mean values are plotted in Fig. 1.
* Corresponding author.
TABLE 1. Range of MICs of flumequine and oxolinic acid
against 83 Scottish isolates of A. salmonicida
Strain type (no. of Test agent MIC (.g/ml) at 22oCa
isolates) 50es90%aRang
Oxolinic acid Oxolinic acid 3.00 7.50 1.00-15.00
resistant (38)
Flumequine 2.00 4.00 0.10-20.00
Oxolinic acid Oxolinic acid 0.030 0.40 0.01-0.75
susceptible (45)
Flumequine 0.075 0.10 0.075-0.50
a 50%o and 90%o, MICs for 50 and 90% of isolates tested, respectively.
After 1 h of exposure, neither oxolinic acid nor flumequine
was bactericidal, with approximately 100% of the bacteria
surviving at concentrations of up to 100 times the MIC for
the bacteria (data not shown). Furthermore, oxolinic acid
was merely bacteriostatic even after 6 h of exposure, with
approximately 100% of the bacteria surviving (Fig. 1). In
contrast, flumequine was bactericidal, killing 90% and >99%
of the bacteria after 3 and 6 h of exposure, respectively, to
concentrations above five times the MIC at 22°C (Fig. 1).
The bactericidal activity of flumequine may be of use in
eliminating the asymptomatic carrier state of furunculosis;
TABLE 2. MICs of oxolinic acid and flumequine for isolates
used in bactericidal activity and mutation frequency studies
MIC (fg/ml)
Isolatea
Oxolinic acid Flumequine
MT363b 0.03 0.10
MT736 0.015 0.075
MT364 7.50 2.00
MT472 3.00 3.00
MT490b 0.03 0.10
MT494b 0.03 0.10
MT744b 0.03 0.075
MT747b 0.03 0.10
a All strains were isolated from separate outbreaks of furunculosis in
Scotland.b Strains used in the mutation frequency study.
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TABLE 3. Range of mutation frequencies for five oxolinic acid-susceptible isolates of A. salmonicida
Mutation frequency at:
Test agent
5x MIC lOx MIC 20x MIC
Oxolinic acid 3.3 x 10-9-3.64 x 10-8 1.7 x 10-9-6.4 x 10-8 <1.1 x 10-9-3.2 x 10-8
Flumequine 1.5 x 10-9-2.0 x 10-8 <3.3 x 10-10 <3.33 x 10-10
indeed, Scallan and Smith (8) obtained promising results
with flumequine in reducing carriers in salmon and trout.
Resistance to antibacterial agents is a serious problem in
the aquaculture industry (5, 11), and the effective life of an
antibiotic is determined largely by the rate at which resis-
tance to it develops during therapy. Determination of the
frequency of chromosomal mutation that leads to resistance
can provide an indication of the rate at which resistance to a
quinolone will develop (9), since plasmid-mediated resis-
tance to the quinolones has not yet been identified clinically
(3). Mutation frequencies were determined for five oxolinic
acid- and flumequine-susceptible isolates of A. salmonicida,
as follows. Conical flasks containing 250 ml of drug-free TSB
were inoculated with the A. salmonicida isolates and were
shaken overnight at 22°C. The resulting cultures were cen-
trifuged at 11,500 x g and resuspended in 2 ml of fresh TSB
to give cell concentrations in excess of 1010 CFU/ml. Ali-
quots (0.1 ml) of undiluted and 10-1, 102, i0- and 10-
dilutions of the cultures were then spread onto TSA plates
containing antibiotic at 5, 10, and 20 times the MIC. The
plates were incubated at 22°C and were examined daily for 7
days for the presence of resistant colonies. Resistant colo-
nies were subcultured onto TSA containing antibiotic to
verify resistance, and colonies were identified to the species
1000l
*1
0.1 1.0
Dmg Concentratlon (,gmi)
FIG. 1. Bactericidal activities of oxolinic acid and flumequine
against A. salmonicida MT363. Percent survival after 6 h of expo-
sure to oxolinic acid (U), 3 h of exposure to flumequine (A), and 6
h of exposure to flumequine (O) is shown.
level by using a latex bead agglutination kit (Aquaculture
Vaccines Ltd., Saffron Walden, United Kingdom).
A. salmonicida isolates developed resistance to flume-
quine at significantly lower frequencies than they did to
oxolinic acid (Table 3). Indeed, resistance to flumequine
developed at less than 1/10th the frequency that resistance to
oxolinic acid did.
In conclusion, flumequine was only marginally more ac-
tive than oxolinic acid in terms of its' MIC. However,
flumequine was bactericidal at concentrations slightly above
the MIC after 6 h of exposure, whereas oxolinic acid was
merely bacteriostatic. This bactericidal activity, combined
with the lower mutation frequencies and better pharmacoki-
netics (6, 10), suggest that flumequine has' several advan-
tages as a potential alternative to oxolinic acid for use in
Scotland. This is supported by the encouraging results
achieved with flumequine during furunculosis therapy in
Norway.
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